Alnylam Pharmaceuticals
ALNY
#577
Rank
โ‚ฌ37.07 B
Marketcap
279,58ย โ‚ฌ
Share price
-1.73%
Change (1 day)
19.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -โ‚ฌ0.21 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ3.21 Billion. In 2024 the company made an earning of -โ‚ฌ0.21 Billion, an increase over its 2023 earnings that were of -โ‚ฌ0.27 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-โ‚ฌ0.21 Billion-24.59%
2023-โ‚ฌ0.27 Billion-67.84%
2022-โ‚ฌ0.83 Billion36.93%
2021-โ‚ฌ0.61 Billion-8.04%
2020-โ‚ฌ0.66 Billion-15.66%
2019-โ‚ฌ0.79 Billion12.23%
2018-โ‚ฌ0.7 Billion62.91%
2017-โ‚ฌ0.43 Billion17.78%
2016-โ‚ฌ0.37 Billion43.44%
2015-โ‚ฌ0.26 Billion60.69%
2014-โ‚ฌ0.16 Billion98.2%
2013-โ‚ฌ79.43 Million
2011-โ‚ฌ46.85 Million27.48%
2010-โ‚ฌ36.75 Million-10.92%
2009-โ‚ฌ41.26 Million95.77%
2008-โ‚ฌ21.08 Million
2006-โ‚ฌ33.76 Million-9.13%
2005-โ‚ฌ37.16 Million34.74%
2004-โ‚ฌ27.58 Million36.79%
2003-โ‚ฌ20.16 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚ฌ13.97 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚ฌ7.77 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.47 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚ฌ0.22 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚ฌ40.54 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚ฌ0.14 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ1.83 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚ฌ0.12 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA